Clarence L. Dellio
Keine laufenden Positionen mehr
Profil
Clarence L.
Dellio served as Vice President-Manufacturing at Becton, Dickinson & Co. He then worked as Chief Operating Officer & Senior Vice President at XOMA Corp.
from 1984 to 2004.
From 2004 to 2008, he was the President & Chief Operating Officer at Neosil, Inc. In 2011 to 2013, he served as Chief Operating Officer at Aevi Genomic Medicine, Inc. Mr. Dellio obtained his undergraduate degree from Bentley University.
Ehemalige bekannte Positionen von Clarence L. Dellio
| Unternehmen | Position | Ende |
|---|---|---|
| AEVI GENOMIC MEDICINE, INC. | Geschäftsführer | 31.12.2013 |
Neosil, Inc.
 Neosil, Inc. Pharmaceuticals: MajorHealth Technology Neosil, Inc. manufactures pharmaceutical products. It develops hair growth products and anti-microbial agent for acne and anti-infective use. The company was founded by Sam Sawan in 2004 and is headquartered in Emeryvill, CA. | Präsident | - |
| XOMA CORPORATION | Geschäftsführer | 01.01.2004 |
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | - |
Ausbildung von Clarence L. Dellio
| Bentley University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XOMA CORPORATION | Health Technology |
| BECTON, DICKINSON AND COMPANY | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Neosil, Inc.
Neosil, Inc. Pharmaceuticals: MajorHealth Technology Neosil, Inc. manufactures pharmaceutical products. It develops hair growth products and anti-microbial agent for acne and anti-infective use. The company was founded by Sam Sawan in 2004 and is headquartered in Emeryvill, CA. | Health Technology |
Aevi Genomic Medicine, Inc.
 Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
